Van Agthoven M, Fokkens WJ, van de Merwe JP, van Bolhuis EM, Uyl-de Groot CA, Busschbach JJV. Quality of life of patients with refractory chronic rhinosinusitis, effects of filgrastim treatment. Am J of Rhinol 2001; 15: 231-238.

Van Agthoven M, van Ineveld BM, de Boer MF, Leemans CR, Knegt PP, Snow GB, Uyl-de Groot CA. The costs of head and neck oncology. primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001; 37: 2204-2211.

Van Agthoven M, Metselaar HJ, Tilanus HW, de Man RA, IJzermans JNM, van Ineveld BM. A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure. Transpl Int 2001; 14: 87-94.

Van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin’s lymphoma or Hodgkin’s disease: a prospective randomised trial. Eur J Cancer 2001; 37 (14): 1781-1789.

Bleichrodt H, Johannesson M. Time Preference for Health: A Test of Stationarity versus Decreasing Timing Aversion. J Math Psychol 2001; 45: 265-282.

Bleichrodt H, Pinto JL, Wakker PP. Making descriptive use of prospect theory to improve the prescriptive use of expexted utility. Management Science 2001; 47: 1498-1514.

Bleichrodt H. Probability weighting in choice under risk: an empirical test. The journal of Risk and Uncertainty 2001; 23 : 185-198.

Bouwmans CAM, Bandel AP, Sol JCA, Ineveld BM van, Klazinga NS. Met het ziekenhuis de lucht in? ZM Magazine 2001; 17: 13-17.

Brouwer WBF, Rutten FFH. Health economics: a bridge over troubled water. Eur J Public Health 2001; 11: 234-36.

Brouwer WBF, Van Exel NJA. Zorgelijk vervoersbeleid. ESB 2001; 86: 328-29.

Brouwer WBF, Hermans HEGM. Europese regelgeving grijp in op nationaal zorgstelsel. TSG 2001;79: 176-79.

Brouwer WBF, Schut FT. Ethische dilemma’s in het nieuwe zorgstelsel. ESB Dossier 2001; 86: D7.

Brouwer WBF, Stoop AP. Maak het wachten dragelijker: vaste afspraken binnen maximum levertijden. Medisch Contact 2001; 56: 908-9.

Brouwer WBF, Hermans HEGM, Van Doorslaer EKA. Zorg in en om Europa. ZorgVisie 2001; 31: 24-9.

Brouwer WBF, Rutten FFH. GVS geeft verkeerde signalen. ESB 2001; 86: 884-886.

Busschbach JJV, Doerga EV, Kamerling MM, Plandsoen MJ, Vleuten HAvd, Vliet Av, Wel PC vd, IJperen MJv. Verpleeghuiszorg thuis kan doelmatig: Ouderen stellen lagere eisen aan veiligheid en service bij extramurale verpleeghuiszorg. Ouderenzorg 2001; 4: 24-6.

Busschbach JJV, Van Hout BA. Snel verdiend. Nieuwe medicatie kan kosteneffectief zijn. Medisch Contact 2001; 56: 1815-7.

Chevat C, Pena BM, Al MJ, Rutten FFH. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics 2001; 19 Suppl 1: 17-32.

Van Exel NJA, Brouwer WBF. Lekker belangrijk. ESB 2001; 86: 155-57.

Feenstra TL, Van Genugten MLL, Hoogenveen RT, Wouters EF, Rutten-van Mölken MPMH. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease. A model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164: 590-6.

Gorter JW, Oostenbrink JB, Tangelder MJD (for the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group and the Dutch BOA Study Group). Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease. Thromb Haemost 2001; 85: 52-6.

Hakkaart-van Roijen L, Verboom P, Redekop WK, Touw KR, Rutten FFH. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis.Pharmacoeconomics 2001; 19: 599-608.

Harris A, Buxton M, O’Brien B, Rutten F, Drummond M. Using economic evidence in reimbursement decisions for health technologies: experience in 4 countries. Expert Review Pharmacoeconomics Outcomes Research 2001; 1: 7-12.

Van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat? Eur Heart J 2001; 22: 751-61.

Jansen R, Redekop WK, Rutten FFH. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis. Pharmacoeconomics 2001; 19: 401-10.

Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12: 417-27.

Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356-61.

Li N, van Agthoven M, Willemse PHB, Uyl-de Groot CA. A Cost-Utility Analyses Comparing Second-line Chemotherapy Schemes In Patients With Metastatic Breast Cancer. Anticancer Drugs 2001; 12: 533-40.

McDonnell J, Busschbach JJV, Kok E, Van Exel J, Stolk E, Koopmanschap M, Rutten FFH. Lower urinary tract symptoms suggestive of benign prostatic obstruction – Triumph: health-economical analysis. Eur Urol 2001; 39: 37-41.

McDonnell J, Redekop WK, Roer Nvd, Goes E, Ruitenberg A, Busschbach JJV, Breteler MMG, Rutten FFH. The cost of treatment of Alzheimers’s disease in The Netherlands. A regression-based simulation model.Pharmacoeconomics 2001;19:379-90.

Oostenbrink JB, Rutten-van Mölken MPMH, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 2001; 10: 184-91.

Oostenbrink JB, Tangelder MJD, Busschbach JJv, Van Hout BA, Buskens E, Algra A, Lawson JA, Eikelboom BC; Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group. Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass surgery, J Vasc Surg 2001; 34: 254-62.

Poley MJ, Stolk EA, Langemeijer RATM, Molenaar JC, Busschbach JJV. The cost-effectiveness of neonatal surgery and subsequent treatment for congenital anorectal malformations. J Pediatr Surg 2001; 36: 1471-8.

Rhemrev JPT, Lens JW, McDonnell J, Schoemaker J, Vermeiden JPW. The postwash total progressively motile cell count is a reliable predictor of total fertilization failure during in-vitro fertilization treatment. Fertil Steril 2001; 76: 884-891.

Ruitenberg A, Kalmijn S, de Ridder MAJ, Redekop WK, van Harskamp F, Hofman A, Launer LJ, Breteler MM. Prognosis of Alzheimer’s Disease: The Rotterdam Study. Neuroepidemiology 2001; 20: 188-195.

Rutten FFH, Busschbach JJV. How to define a basic package of health services for a tax funded or social insurance based health care system? (editorial) Eur J Health Econ (HEPAC) 2001; 2: 45-6.

Rutten FFH, Bleichrodt H, Brouwer WBF, Koopmanschap M, Schut E. Book review: handbook of health economics. J Health Econ 2001; 20: 855-879.

Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, Brand MJv d, Herwerden LAv, Morel MA, van Hout BA. Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-24.

Stolk EA, Busschbach JJV. A comparison of the EuroQol and the Health Utilities Index in patients treated for congenital anomalies. Eur J Health Econ (HEPAC) 2001; 2: 54-60.

Stooker T, van Acht JW, van Barneveld EM, van Vliet RCJA, van Hout BA, Hessing DJ, Busschbach JJV. Costs in the Last Year of Life in the Netherlands. Inquiry 2001; 38: 73-80.

Stoop AP, Brouwer WBF. Huidige discussie over wachtlijsten niet zinvol. Medisch Contact 2001; 56: 1610-1612.

Suryapranata H, Ottervanger JP, Nibbering E, Van ‘t Hof AW, Hoorntje JC, De Boer MJ, Al MJ, Zijlstra F. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocaridal infarction.Heart 2001; 85: 667-71.

van Tinteren H, Hoekstra OS, Smit EF, Verboom P, Boers M; PLUS Study Group. Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography. Control Clin Trials 2001; 22: 89-98.

Touw CR, Hakkaart-van Roijen L, Verboom P, Paul C, Rutten FFH, Finlay AY. Quality of life and clinical outcome in psorias patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-72.

Uyl-De Groot CA, Gelderblom-Den Hartog J, Huijgens PC, Willemze R, Ineveld BM van. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the netherlands. J Hematother Stem Cell Res 2000; 10: 187-92.

Vellenga E, van Agthoven M, Croockewit AJ, Verdonck LF, Wijermans PJ, van Oers MH, Volkers CP, van Imhoff GW, Kingma T, Uyl-De Groot CA, Fibbe WE. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114: 319-326.

Verkerk MA, Busschbach JJV, Karssing ED. Health-related quality of life research and the capability approach of Amartya Sen. Qual Life Res 2001; 10: 49-55.